Professor Sir Rory Collins
- ATLAS: International ATLAS (Adjuvant Tamoxifen Longer Against Shorter) Breast Cancer Treatment Trial
- ATT: Antithrombotic Trialists' Collaboration
- CTT: Cholesterol Treatment Trialists' Collaboration
- HPS3 / TIMI 55 - REVEAL : Randomised EValuation of the Effects of Anacetrapib through Lipid-modification
- HPS: Heart Protection Study
- International Study of Infarct Survival (ISIS)
- Mexico City Prospective Study
- Oxford Cholesterol Study
- Research Regulation
- SEARCH: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine
- The Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
- Trials Methodology
- UK Biobank
Head of Nuffield Department of Population Health and BHF Professor of Medicine and Epidemiology
Rory Collins studied Medicine at St Thomas’s Hospital Medical School, London University (1974-1980), and Statistics at George Washington University (1976-7) and at Oxford University (1982-3).
In 1985 he became co-director, with Professor Sir Richard Peto, of the University of Oxford's Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU). In 1996, he was appointed Professor of Medicine and Epidemiology at Oxford, supported by the British Heart Foundation.
He became Principal Investigator and Chief Executive of the UK Biobank prospective study of 500,000 people in September 2005. From July 2013, he became the Head of the Nuffield Department of Population Health at Oxford University.
His work has been in the establishment of large-scale epidemiological studies of the causes, prevention and treatment of heart attacks, other vascular disease, and cancer. He was knighted in 2011 for his services to science.
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Baigent C. et al, (2005), Lancet, 366, 1267 - 1278
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Antithrombotic Trialists' Collaboration None., (2002), BMJ, 324, 71 - 86
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
Heart Protection Study Collaborative Group None., (2002), Lancet, 360, 7 - 22
Human genetics uncovers
as an obesity-independent therapeutic target for diabetes
Nag A. et al, (2022), Science Advances, 8
Adiposity and NMR-measured lipid and metabolic biomarkers among 30,000 Mexican adults.
Aguilar-Ramirez D. et al, (2022), Commun Med (Lond), 2
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.
Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet (London, England), 400, 832 - 845
New Horizons: the value of UK Biobank to research on endocrine and metabolic disorders.
Bešević J. et al, (2022), J Clin Endocrinol Metab, 107, 2403 - 2410
Genotyping, sequencing and analysis of 140,000 adults from the Mexico City Prospective Study
Ziyatdinov A. et al, (2022)